Condition: Alcohol Use Disorder (AUD) · Post Traumatic Stress Disorder (PTSD) · Insomnia · Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outcome assessments via in-person clinic visits on days 7 and 14.
This description comes directly from the study's public registry record.
Scott Lane, PhD · 713-486-2535 · scott.d.lane@uth.tmc.edu
Lara Ray, PhD · lararay@psych.ucla.edu
Always discuss trial participation with your own doctor first.
| University of California - Los Angeles | Los Angeles, California, United States | Recruiting |
| The University of Texas Health Science Center - Houston | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06679062